 |
市場調查報告書
商品編碼
1532415
非小細胞肺癌市場：按類型、治療、最終用戶、地區Non-Small Cell Lung Cancer Market, By Type, By Treatment, By End User, By Geography |
||||||
價格
簡介目錄
預計2024年全球非小細胞肺癌市場規模為261億美元，預計2031年將達491.1億美元，2024年至2031年複合年成長率為9.4%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 2024年市場規模 | 261億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測 2024-2031 年複合年成長率： | 9.40% | 2031年價值預測 | 491.1億美元 |
圖：2024 年按地區分類的非小細胞肺癌市場佔有率 (%)
非小細胞肺癌 (NSCLC) 是最常見的肺癌，約佔所有肺癌的 85%，是全球癌症相關死亡的主要原因之一。全球非小細胞肺癌市場的成長是由吸煙習慣和環境污染的增加、先進標靶治療方案的研發活動的增加以及對標靶和個人化治療的需求不斷成長等因素所推動的。然而，高昂的處理成本阻礙了市場的成長。
市場動態：
全球非小細胞肺癌市場成長的驅動力是已開發國家和新興國家吸菸習慣的增加、環境污染水平的上升以及人口老化。據世界衛生組織稱，全球每年報告約 180 萬新發肺癌病例，其中大多數為非小細胞肺癌 (NSCLC)。標靶治療和癌症治療方法的進步為市場相關人員提供了機會。然而，與標靶治療相關的高成本以及低收入國家缺乏認知正在阻礙市場成長。此外，測試過程中藥物失敗的風險也會對研發活動產生負面影響。
本研究的主要特點
- 該報告對全球非小細胞肺癌市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
- 它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
- 根據公司亮點、產品系列、主要亮點、績效和策略等參數，對全球非小細胞肺癌市場的主要企業進行概況分析。
- 該報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球非小細胞肺癌市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 透過用於分析全球非小細胞肺癌市場的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 研究目的與前提
- 研究目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管場景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
第4章全球非小細胞肺癌市場：COVID-19 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第5章全球非小細胞肺癌市場：依類型分類，2019-2031
- 腺癌
- 鱗狀細胞癌
- 大細胞癌
- 大細胞神經內分泌腫瘤
第6章 全球非小細胞肺癌市場：依治療方法分類，2019-2031 年
- 化療
- 標靶治療
- Bevacizumab（Avastin）
- Necitumumab（Portrazza）
- Ramucirumab（CYRAMZA）
- 免疫療法
- 納武單抗（Opdivo）
- Atezolizumab（TECENTRIQ）
- 其他
第 7 章 全球非小細胞肺癌市場：依最終使用者分類，2019-2031 年
- 醫院
- 居家照護
- 專科診所
- 其他
第8章全球非小細胞肺癌市場：依地區分類，2019-2031
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
第9章 競爭格局
- 公司簡介
- F. Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck &Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson &Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
第10章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第11章 章節
- 參考
- 調查方法
簡介目錄
Product Code: CMI241
Global non-small cell lung cancer market is estimated to be valued at USD 26.10 Bn in 2024 and is expected to reach USD 49.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 26.10 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 9.40% | 2031 Value Projection: | US$ 49.11 Bn |
Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2024
Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.
Market Dynamics:
Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.
Key features of the study:
- This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.
Detailed Segmentation-
- By Type
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Large Cell Neuroendocrine Tumors
- Treatment
- Chemotherapy
- Targeted Therapy
- Bevacizumab
- Necitumumab
- Ramucirumab
- Immunotherapy
- Nivolumab
- Atezolizumab
- Others
- End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Hoffmann-La Roche Ltd
- Honeywell International Inc.
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Non-Small Cell Lung Cancer Market, By Type, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Adenocarcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Squamous Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Large Cell Carcinoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Large Cell Neuroendocrine Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Bevacizumab (Avastin)
- Necitumumab (Portrazza)
- Ramucirumab (Cyramza)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Non-Small Cell Lung Cancer Market, By End User, 2019 - 2031, (USD Bn)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospitals
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Home Care
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Non-Small Cell Lung Cancer Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Honeywell International Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Celgene Corporation
- Amgen Inc.
- Johnson & Johnson
- Gilead Sciences, Inc.
- AbbVie Inc.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- F. Hoffmann-La Roche Ltd
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. Section
- References
- Research Methodology
- About Us and Sales Contact
